Metabolism News and Research

Latest Metabolism News and Research

Study examines how individuals utilize benefits and services under Medicare program

Findings released today and detailed in the analysis Low Consumption and Higher Medicare Cost: Consumption Clusters in a Medicare Fee-for-Service Population, examine how individuals utilize benefits and services under the Medicare program.

25 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

24 Feb 2010

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa.

From Parexel 24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

Gene study provides new clues to fight infections

Investigators at The Methodist Hospital Research Institute in Houston examined for the first time the long-term response to strep throat on a genome-wide level, shedding light on how group A streptococcus interacts with the patient's immune system and attempts to circumvent it.

23 Feb 2010

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss.

23 Feb 2010

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Chiltern International Limited, a global contract research organization (CRO), announced its latest collaboration with Charles River Laboratories, Inc. As part of this collaboration, Chiltern Early Phase will partner with Charles River to conduct and support early phase radiolabelled studies.

22 Feb 2010

Children born through assisted reproduction at greater risk of obesity and type 2 diabetes related defects

More than three million children have been born as a result of assisted reproductive technologies since the birth of the first "test tube baby" in 1978. While the majority of these children are healthy and normal, as a group they are at greater risk of certain kinds of birth defects and being low birth weight, which is associated with obesity, hypertension and type 2 diabetes later in life.

22 Feb 2010

Researchers identify specific metabolic profiles that predict risk of heart attack and death

Tiny bits of molecular "trash" found in circulating blood appear to be good predictors of cardiovascular disease and untimely death, say researchers at Duke University Medical Center.

19 Feb 2010

University of Missouri researchers visualize "terminals" inside proline degrading enzyme

If subway terminals didn't exist and people had to exit subway stations to switch subway lines, transit time would increase. People also may encounter distractions, such as grabbing a cup of coffee, instead of getting on the other line. Molecules also use "terminals" to save transit time during enzyme-catalyzed processes. Using advanced X-radiation techniques, University of Missouri researchers were able to visualize one of these terminals inside of an enzyme that degrades proline, which is an amino acid that has a central role in metabolism.

19 Feb 2010

Study analyzes genome and exome sequence data from hunter-gatherer participants of South Africa

In a study published online today in Nature, a team of researchers from Penn State University and the University New South Wales present the complete genome sequences of an indigenous hunter-gatherer from the Kalahari Desert and a Bantu from southern Africa, along with three additional whole exome sequences of Kalahari hunter-gatherers.

19 Feb 2010

ATM tumor-suppressor also recognizes damage caused by ROS and orders autophagy

ATM, a protein that reacts to DNA damage by ordering repairs or the suicide of the defective cell, plays a similar, previously unknown role in response to oxidative damage outside of the nucleus, researchers report this week in the online version of the Proceedings of the National Academy of Sciences.

19 Feb 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

Cellular metabolism plays a key role in cancer development

It is not unusual to hear people blame their metabolism after gaining a few pounds. But changes in metabolism - the process that shapes how our bodies turn food into energy -- can have much more sinister effects than making it hard to fit into your favorite jeans.

19 Feb 2010

Steroids and weight loss products can accelerate hair loss, says hair loss expert

In a study due to be released next month, the world's leading hair transplant and hair loss expert Dr. Larry Shapiro will show that men and women have been losing their hair from using popular weight loss and work out products that contain whey protein isolate- and it's not just their genes that are to blame.

19 Feb 2010

HPV DNA testing vital in identification of cervical cancer

Roche Molecular Systems, Inc. announced today that preliminary data from its ATHENA (Addressing THE Need for Advanced HPV Diagnostics) trial support the importance of screening for human papillomavirus (HPV) genotypes that put women at highest risk for developing cervical cancer. ATHENA is a prospective, double-blind, multi-centered, 47,000-patient, U.S.-registration trial designed to demonstrate the effectiveness of HPV detection as part of a cervical cancer screening program.

18 Feb 2010

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

Researchers at the Swedish medical university Karolinska Institutet have discovered a protein that is crucial in mediating the anti-inflammatory actions of nuclear lipid receptors. The findings, published in the research journal Genes & Development, link lipid metabolism and inflammation and open up new possibilities for developing treatments of metabolic diseases associated with inflammation, such as diabetes and atherosclerosis.

17 Feb 2010

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

AB SCIEX, a global leader in life science analytical technologies, today announced that it has acquired the liquid chromatography business of Eksigent Technologies. This acquisition significantly strengthens AB SCIEX’s position in liquid chromatography, which is a key technology used frequently in a broad range of life science applications such as protein biomarker research, drug discovery and basic research.

16 Feb 2010

Metabolism News and Research

Latest Metabolism News and Research

Study examines how individuals utilize benefits and services under Medicare program

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Gene study provides new clues to fight infections

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Children born through assisted reproduction at greater risk of obesity and type 2 diabetes related defects

Researchers identify specific metabolic profiles that predict risk of heart attack and death

University of Missouri researchers visualize "terminals" inside proline degrading enzyme

Study analyzes genome and exome sequence data from hunter-gatherer participants of South Africa

ATM tumor-suppressor also recognizes damage caused by ROS and orders autophagy

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Cellular metabolism plays a key role in cancer development

Steroids and weight loss products can accelerate hair loss, says hair loss expert

HPV DNA testing vital in identification of cervical cancer

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

AB SCIEX acquires liquid chromatography business of Eksigent Technologies

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep